BRAF and melanoma: To further understand the impact of NRAS Q61K and KRAS G13D mutations on Ras/RAF/MEK/ERK pathway signaling in our BRAF V600E melanoma models, western blotting was carried out for the A375 WT, NRAS Q61K, and KRAS G13D cells after treatment with either dabrafenib, vemurafenib, doxorubicin, or vehicle control, then total cellular protein was harvested for immunoblotting.